FY2018 EPS Estimates for Albireo Pharma Inc Reduced by Analyst (ALBO)
Albireo Pharma Inc (NASDAQ:ALBO) – Investment analysts at Wedbush lowered their FY2018 earnings per share (EPS) estimates for Albireo Pharma in a research report issued to clients and investors on Wednesday, November 14th. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will earn ($3.65) per share for the year, down from their prior estimate of ($3.55). Wedbush has a “Buy” rating and a $69.00 price objective on the stock. Wedbush also issued estimates for Albireo Pharma’s Q4 2018 earnings at ($1.04) EPS, Q2 2019 earnings at ($1.17) EPS, Q3 2019 earnings at ($1.17) EPS, Q4 2019 earnings at ($1.20) EPS, FY2019 earnings at ($4.65) EPS, FY2020 earnings at ($4.79) EPS and FY2021 earnings at ($5.00) EPS.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings data on Tuesday, November 13th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.20). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $1.55 million.
Shares of NASDAQ ALBO opened at $23.96 on Monday. The firm has a market cap of $316.48 million, a P/E ratio of -7.61 and a beta of 1.74. Albireo Pharma has a 1-year low of $21.25 and a 1-year high of $39.87.
In other Albireo Pharma news, insider Ronald Harold Wilfred Cooper purchased 1,026 shares of the firm’s stock in a transaction on Tuesday, November 13th. The stock was bought at an average cost of $25.02 per share, for a total transaction of $25,670.52. Following the completion of the purchase, the insider now owns 7,760 shares in the company, valued at approximately $194,155.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.60% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in ALBO. Northern Trust Corp raised its stake in Albireo Pharma by 60.3% in the first quarter. Northern Trust Corp now owns 15,766 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 5,932 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Albireo Pharma by 522.4% in the first quarter. BlackRock Inc. now owns 76,780 shares of the biopharmaceutical company’s stock valued at $2,501,000 after purchasing an additional 64,444 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Albireo Pharma in the second quarter valued at about $165,000. Heartland Advisors Inc. increased its holdings in shares of Albireo Pharma by 36.9% in the second quarter. Heartland Advisors Inc. now owns 125,000 shares of the biopharmaceutical company’s stock valued at $4,438,000 after purchasing an additional 33,677 shares during the period. Finally, Birchview Capital LP increased its holdings in shares of Albireo Pharma by 58.3% in the second quarter. Birchview Capital LP now owns 38,000 shares of the biopharmaceutical company’s stock valued at $1,349,000 after purchasing an additional 14,000 shares during the period. Institutional investors own 63.24% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.